Teva Pharmaceuticals has received FDA approval and has launched a generic version of Saxenda (liraglutide), which is approved to treat adults and adolescents 12 to 17 years of age who are obese or ...

Teva is releasing a generic version of Novo Nordisk’s Saxenda, a liraglutide injection. Liraglutide injection is indicated for adults with obesity or overweight who also have weight related medical ...

More than 1.1 million prescriptions for the weight-loss drugs Saxenda and Wegovy have been issued in South Korea over the ...

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.